Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward
Authors:
- 1 June 2020
- journal article
- research article
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 26 (6) , 637-651
Abstract
Appropriate empiric therapy reduces mortality and morbidity associated with serious Gram-negative infections. β-lactams (BLs) owing to their safety, efficacy, and coverage spectrum are the most preferred agents for empiric use. Inappropriate use of older penicillins and cephalosporins led to selection and spread of resistant clones. As a result, these valuable agents have lost their reliability compelling clinicians to often use erstwhile last-line therapies such as carbapenems. Excessive carbapenems use imposed collateral damage by selecting difficult-to-treat carbapenem-resistant organisms. Lack of empiric therapeutic options amenable for use in infections caused by contemporary pathogens was realized by the pharmaceutical industry leading to intensive efforts in discovering novel antibiotics. These efforts led to the approval of newer β-lactams and β-lactamase inhibitor (BL-BLI) combination. This review elaborates the past trends in empirical use of BLs and ensuing patterns of resistance emergence in Gram-negatives. Furthermore, a critical appraisal of newer BL-BLIs has been presented to identify the appropriate clinical situations for their use to ensure clinical efficacy coupled with minimal resistance selection. These learning have been derived from past trends of clinical usage of older empiric therapies so that the therapeutic utility of newer agents is preserved for long in light of dwindling global antibiotics pipeline.Keywords
This publication has 112 references indexed in Scilit:
- Carbapenems: Past, Present, and FutureAntimicrobial Agents and Chemotherapy, 2011
- Extended-Spectrum AmpC Cephalosporinase in Acinetobacter baumannii: ADC-56 Confers Resistance to CefepimeAntimicrobial Agents and Chemotherapy, 2011
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance PhenotypesAntimicrobial Agents and Chemotherapy, 2011
- Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2010
- Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical StrainsAntimicrobial Agents and Chemotherapy, 2010
- Affinity of Tomopenem (CS-023) for Penicillin-Binding Proteins in Staphylococcus aureus , Escherichia coli , and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2009
- Establishment of In Vitro Susceptibility Testing Methodologies and Comparative Activities of Piperacillin in Combination with the Penem β-Lactamase Inhibitor BLI-489Antimicrobial Agents and Chemotherapy, 2009
- Delay of Active Antimicrobial Therapy and Mortality among Patients with Bacteremia: Impact of Severe NeutropeniaAntimicrobial Agents and Chemotherapy, 2008
- Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2008
- In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2007